Neurocrine Biosciences, Inc. Share Price Berne S.E.
Equities
NB3
US64125C1099
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
111.6 CHF | -.--% | -.--% | -.--% |
Sales 2024 * | 2.22B 1.99B 174B | Sales 2025 * | 2.55B 2.29B 201B | Capitalization | 13.39B 12B 1,053B |
---|---|---|---|---|---|
Net income 2024 * | 431M 386M 33.88B | Net income 2025 * | 675M 605M 53.05B | EV / Sales 2024 * | 5.13 x |
Net cash position 2024 * | 2B 1.79B 157B | Net cash position 2025 * | 2.81B 2.52B 221B | EV / Sales 2025 * | 4.15 x |
P/E ratio 2024 * |
32.8
x | P/E ratio 2025 * |
21
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.2% |
Latest transcript on Neurocrine Biosciences, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Kevin Gorman
FOU | Founder | 66 | 31/12/91 |
Director of Finance/CFO | 44 | 31/10/17 | |
Jude Onyia
CTO | Chief Tech/Sci/R&D Officer | 60 | 29/11/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Stephen Sherwin
BRD | Director/Board Member | 75 | 31/03/99 |
George Morrow
BRD | Director/Board Member | 72 | 30/09/15 |
Kevin Gorman
FOU | Founder | 66 | 31/12/91 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.02% | 125B | |
+14.32% | 108B | |
-4.84% | 24.57B | |
+3.23% | 22.82B | |
-10.44% | 18.19B | |
-41.74% | 16.54B | |
-13.39% | 16.5B | |
+28.99% | 11.1B | |
+83.48% | 9.22B |
- Stock Market
- Equities
- NBIX Stock
- NB3 Stock